Glaucoma Trial, Recruiting NCT05801471 Sponsor: Centervue SpA Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT05801471
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have glaucoma-related damage to the optic nerve (the nerve connecting the eye to the brain) in both eyes
  • People aged between 40 and 90 years old
  • People whose vision, even with glasses or contact lenses, meets a certain minimum level of clarity (confirm with trial site for exact details)
  • People whose prescription falls within a moderate range — not too short-sighted or long-sighted (between -6 and +6 on the lens scale)
  • People whose astigmatism (irregular curvature of the eye) falls within a moderate range (between -2 and +2 on the lens scale)

Who may not be able to join:

  • People who have had any eye surgery, except for uncomplicated cataract surgery and/or glaucoma surgery in both eyes, if that surgery was done within 6 months before joining the trial
  • People who have any other eye condition, aside from glaucoma, that could affect their field of vision (the full area a person can see without moving their eyes)
  • People taking any medication that could interfere with vision field testing or cause vision field loss
  • People who are unable to produce reliable results during vision field tests
  • People whose glaucoma is at an advanced stage where, in the treating doctor's judgment, a standard type of vision field test (called a 24-2 grid) would not be appropriate for monitoring their condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Luca M. Rossetti, Prof., Clinica oculistica Ospedale San Paolo

Phone: +39 049 501 8399

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centervue SpA
Registry
ClinicalTrials.gov
Start date
6 May 2022
Est. completion
6 November 2028

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Equivalence between Compass and HFA in terms of estimation of the global progression rate (MD progression slope).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov